The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives

Wisdom, Amy J.; Barker, Christopher A.; Chang, Joe Y.; Demaria, Sandra; Formenti, Silvia; Grassberger, Clemens; Gregucci, Fabiana; Hoppe, Bradford S.; Kirsch, David G.; Marciscano, Ariel E.; Mayadev, Jyoti; Mouw, Kent W.; Palta, Manisha; Wu, Cheng-Chia; Jabbour, Salma K.; Schoenfeld, Jonathan D.

doi:10.1016/j.ijrobp.2023.12.046

Cited by 7 publications

(1 citation statement)

References 224 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 RT could be also used in post-ASCT settings where the disease burden is ideally minimal and it is possible to achieve the best possible control of the residual (microscopic) disease by administering a reduced volume and dose. Even if still exploratory, the combination of RT with immune checkpoint inhibitors (i.e., AERN trial) 21 is intriguing considering the potential synergism between RT and anti-PD1 22 which might be considered in the R/R HL. 23 In this context, particle beam RT has been proven to reduce the damage to blood lymphocytes compared to Xrays; moreover, preclinical data showed an increased release of immune-stimulating cytokines after particle beam RT, suggesting that this combined treatments might elicit an anti-tumor immune-mediated response.…”

Section: Relapsed/refractory Hodgkin Lymphomamentioning

confidence: 99%

Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before

Saddi,

Barcellini,

Gotti

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

Classical Hodgkin lymphoma is a lymphoproliferative disease with a good prognosis mainly seen in young people. Nevertheless secondary malignancy, cardiac disease and infertility may affect the long survivors with significant impact on quality of life, morbidity and overall survival. In the last decades several treatment strategies were evaluated to reduce the toxicity of first line treatment such as avoiding radiotherapy or its reduction in terms of dosage and extension. Many trials including interim Positron Emission Tomography evaluation fail to compare efficacy between combined modality treatment versus chemotherapy alone in particular in early stage disease. In this review we analyze which subset of patients could take advantage from proton therapy in terms of toxicity and cost effectiveness.

show abstract

Section: Relapsed/refractory Hodgkin Lymphomamentioning

confidence: 99%